Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

bedaquiline

Small diseases need big picture communications

An early commitment to communications planning in rare diseases is worth the risk

J&J expected to make best use of digital in 2014

Company's strong approach to marketing strategy praised in Digital Futures 2014 survey

- PMLiVE

Infographic: Orphan drug market

A visual guide to the orphan drug and rare disease market for pharma

- PMLiVE

J&J earnings leap on buoyant pharma sales

CEO Alex Gorsky praises "outstanding" pharmaceutical performance

- PMLiVE

Xarelto should not be approved in ACS says FDA panel

Advisory committee votes against new indication for Bayer and J&J’s anticoagulant

Sanofi reception

Sanofi strikes $700m rare diseases deal

Company's Genzyme division will obtain significant rights to Alnylam’s pipeline of orphan drugs

- PMLiVE

J&J’s Imbruvica tops Arzerra in phase III trial

Shows improvement over GSK’s drug in haematological malignancies

- PMLiVE

Cell wall inhibitors for bacterial infections

There are limited pipeline prospects to address this significant health issue

- PMLiVE

Janssen’s Sirturo wins backing for conditional EU licence

CHMP recommends first-in-class multidrug-resistant tuberculosis treatment

- PMLiVE

J&J’s combo diabetes drug held up by FDA

Regulator wants more dosing data on canaglifozin / metformin product

Janssen’s UK head moves to China

Cesar Rodriguez appointed managing director of Xian Janssen

- PMLiVE

EMA: more fee reductions for orphan drugs

Greater incentives introduced for larger companies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links